Rapport Therapeutics (RAPP) Free Cash Flow (2023 - 2026)

Rapport Therapeutics (RAPP) has 4 years of Free Cash Flow data on file, last reported at -$13.1 million in Q1 2026.

• On a quarterly basis, Free Cash Flow rose 35.96% year-over-year to -$13.1 million in Q1 2026; TTM through Mar 2026 was -$80.7 million, a 16.84% decrease from a year earlier, with the FY2025 full-year figure at -$88.1 million, down 31.02% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$13.1 million, up from -$24.9 million in the prior quarter.
• Over the last five years, Free Cash Flow for RAPP reached as high as -$5.5 million in Q3 2023 and fell as low as -$25.1 million in Q2 2025.
• Historically, Free Cash Flow has averaged -$16.9 million across 4 years, with a median of -$17.3 million in 2024.
• Across the five-year window, Free Cash Flow slumped 202.32% in 2024 and soared 35.96% in 2026, its largest moves.
• Year by year, Free Cash Flow stood at -$11.8 million in 2023, then decreased by 24.4% to -$14.7 million in 2024, then sank by 69.51% to -$24.9 million in 2025, then surged by 47.14% to -$13.1 million in 2026.
• Per Business Quant data, the three most recent Free Cash Flow figures were -$13.1 million in Q1 2026, -$24.9 million in Q4 2025, and -$17.6 million in Q3 2025.